---------------------------------------------------------------
 详细处方信息以本药内容附件PDF文件（201222019353436.pdf）的“原文Priscribing Information”为准
---------------------------------------------------------------
部分中文尼索地平处方资料（仅供参考）

药物名称：Nisoldipine, Bay-k-5552, Sular, Baymycard, Syscor

化学名：(?-2,6-Dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylic acid methyl 2-methylpropyl diester；异丁基甲基( )-1,4-二氢-2,6-二甲基-4-(0-硝基苯)-3,5-吡啶二羧酸酯
 
药剂名称：尼索地平、硝苯异丙啶、Bay—K—5552，Bayer—5552．
    
药效学：本品为二氢吡啶类钙拮抗剂。对平滑肌、心肌的钙通道有特异阻断作用，可使周围血管扩张、阻力下降，从而使血压下降。还可使冠脉血流量增加，改善心血流，其作用比硝苯啶强而持久，且几乎无负性肌力作用。
    
药理作用：
本品为二氢吡啶类钙拮抗剂，能阻止心肌和血管平滑肌对钙离子的摄取，具有选择性扩张冠状动脉和外周血管的作用，改善心肌供血，降低外周阻力，从而降低心肌耗氧，增强心肌对缺氧的耐受性，降低高血压病人血压。
降压作用呈剂量依赖性。在引起血压下降的同时，对呼吸和中枢神经系统无明显影响。
    
作用用途：治疗原发性轻、中度高血压病，防心绞痛
    
用法用量：口服用药，成人每次5-10mg，每日2次，早晚各一次
    
不良反应：有时出现轻度、一过性心悸、面红、头晕、耳鸣、乏力、恶心、皮疹等。
    
禁 忌 症：
孕妇禁用
过敏者者禁用
    
注意事项：
血压过度降低者、严重肝功能障碍者及高龄患者应慎用
停药时应逐渐减量
哺乳期妇女如服用，应先停止哺乳

SULAR (nisoldipine) is formulated in a “Slow Quick” extended-release Geomatrix delivery system1
•Nisoldipine is initially released at a constant rate in the proximal gastrointestinal (GI) tract
— Some nisoldipine undergoes metabolism to inactive byproducts in the proximal GI tract
•The initial release is followed by a quick burst in the distal GI tract
— Reducing further metabolism in the proximal GI tract
— Providing therapeutic levels of nisoldipine throughout the remaining daily dosing cycle
•15% less nisoldipine per dose

Controlled release is achieved by constructing a tablet of 2 basic components

This combination of layers, each with different rates of swelling, gelling and erosion, is what accounts for the rate of drug release
Indication:
SULAR is indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents.

Important Safety Information:
The most common adverse events, reported in US placebo-controlled trials, were peripheral edema, headache, and dizziness. In rare cases, some patients, particularly those with severe obstructive coronary artery disease, have developed increased frequency, duration, and/or severity of angina, or acute myocardial infarction on starting calcium channel blocker therapy or at the time of dosage increase. Safety of SULAR in patients with heart failure has not been established. SULAR should be administered cautiously in patients over the age of 65 and in those with severe hepatic dysfunction. Because nisoldipine, like other vasodilators, decreases peripheral vascular resistance, careful monitoring of blood pressure during the initial administration and titration of SULAR is recommended. SULAR should not be taken with grapefruit products.

Please click here for full prescribing information.

Your Healthcare Provider can give you more information about Sular or call (800) 849-9707 ext 1454. Ask your Healthcare Provider if Sular may be right for you.

---------------------------------------------------------------
 详细处方信息以本药内容附件PDF文件（201222019353436.pdf）的“原文Priscribing Information”为准
---------------------------------------------------------------